| Peer-Reviewed

Chitotriosidase Activity in Different Stages of Hepatitis C. It may a Possible Tumor Marker for Hepatocellular Carcinoma

Received: 24 December 2013     Published: 10 March 2014
Views:       Downloads:
Abstract

Chitotriosidase is synthesized and secreted especially in activated macrophages. The aim of this study was to evaluate chitotriosidase activity in patients with various stages of hepatitis C. The study included a total of 90 patients. The patients were divided into four groups. Group 1 included 54 patients with chronic active hepatitis, Group 2 included 20 patients with recovered HCV, Group 3 included 6 patients with HCV induced hepatocellular carcinoma, and Group 4 included 10 patients with HCV cirrhosis. Chitotriosidase activity was measured with spectrophotometry (SigmaAldrich ®). The mean chitotriosidase activity of the four groups was 0,927u/L (0.804u/L in Group 1, 0.521u/L in Group 2, 3.211u/L in Group 3 and 1.030u/L in Group 4). Chitotriosidase activity was significantly higher in Group 3. ROC analysis, used to evaluate chitotriosidase activity for the diagnosis of hepatocellular carcinoma, showed that chitotriosidase activity of 0,935 was below the curve (CI: 95%; 0,862 - 0,976), which was statistically significant (p= 0,0001). The cut-off value was >1,098 with a sensitivity of 100% and a specifity of 81%. Chitotriosidase activity can be a marker with a high sensitivity and specifity for the diagnosis of hepatocellular carcinoma.

Published in Journal of Cancer Treatment and Research (Volume 2, Issue 1)
DOI 10.11648/j.jctr.20140201.12
Page(s) 5-8
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2014. Published by Science Publishing Group

Keywords

Chitotriosidase, Hepatitis C, Hepatocellular Carcinoma

References
[1] Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. version 2.0. Lyon: IARC Press, 2004.
[2] El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127:S27–S34.
[3] Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35–S50.
[4] Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208–1236.
[5] El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–750.
[6] Marrero A, Feng Z, Wang Y. Alpha- Fetoprotein, Des- Gamma Carboxyprothrombin, And Lectin-Bound Alpha-Fetoprotein In Early Hepatocellular Carcinoma. Gastroenterology 2009;137:110–118.
[7] Colli A, Fraquelli M, Conte D. Alpha-fetoprotein and hepatocellular carcinoma. Am J Gastroenterol 2006;101:1939–1941.
[8] Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003;139:46–50.
[9] Fujikawa T,Shiraha H, Yamamoto K. Significance of Des-gamma-carboxy Prothrombin Production in Hepatocellular Carcinoma. Acta Med. Okayama 2009; 63(6): 299-304.
[10] Ono M, Ohta H, Ohhira M, Sekiya C, Namiki M. Measurement of immunoreactive prothrombin precursor and vitamin-K dependent gamma-carboxylation in human hepatocellular carcinoma tissues: decreased carboxylation of prothrombin precursor as a cause of des-gamma-carboxyprothrombin synthesis. Tumour Biol 1990; 11: 319–326.
[11] Liebman HA. Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy) prothrombin. Cancer Res 1989;49: 6493–6497.
[12] Brurberg MB, Nes IF, Eijsink VGH. Comparative studies of chitinases A and B from Serratia marcescens. Microbiology 1996;142: 1581–1589.
[13] Kuranda MJ, Robbins PW. Chitinase is required for cell separation during growth of Saccharomyces cerevisiae. J. Biol. Chem. 1991;266: 19758–19767.
[14] Sakuda S, Isogai A, Matsumoto S, Suzuki A. Search for microbial insect growth regulators. II. Allosamidin, a novel insect chitinase inhibitor.J. Antibiot. (Tokyo) 1987;40: 296–300.
[15] Flach J, Pilet PE, Jolles P. What's new in chitinase research? Experientia (Basel) 1992;48: 701–716.
[16] Hawtin RE, Arnold K, Ayres MD, Zanotto PMD, Howard SC, Gooday GW, Chappell LH, Kitts PA, King LA, Possee RD. Identification and preliminary characterization of a chitinase gene in the Autographa californica nuclear polyhedrosis virus genome. Virology 1995;212: 673–685
[17] Vinetz JM, Dave SK, Specht CA, Brameld KA, Xu B, Hayward R, Fidock DA. The chitinase PfCHT1 from the human malaria parasite Plasmodium falciparum lacks proenzyme and chitin-binding domains and displays unique substrate preferences. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 14061–14066
[18] Kzhyshkowska J, Gratchev A, Goerdt S. Human Chitinases and Chitinase-Like Proteins as Indicators for Inflammation and Cancer. Biomark Insights. 2007; 2: 128–146
[19] Wajner A, Michelin K, Burin MG, Pires RF, Pereira MLS , Giugliani R , Coelho JC Comparison between the biochemical properties of plasma chitotriosidase from normal individuals and from patients with Gaucher disease, GM1-gangliosidosis, Krabbe disease and heterozygotes for Gaucher disease. Clinical Biochemistry 2007;40: 365–369
[20] Seibold MA , Donnelly S, Solon M, Innes A, Woodruff PG . Chitotriosidase is the primary active chitinase in the human lung and is modulated by genotype and disease. JAllergy Clin Immunol. 2008; 122(5): 944–950.
[21] Kzhyshkowska J, Gratchev A, Human Chitinases and Chitinase-Like Proteins as indicators for Inflammation and Cancer Goerdt Biomarker Insights 2007; 2: 128–146
[22] Kazakova MH, Sarafian VS. YKL-40--a novel biomarker in clinical practice? Folia Med (Plovdiv). 2009 Jan-Mar;51(1):5-14
Cite This Article
  • APA Style

    Engin ALTINTAS, Serkan Yaras, Burak CIMEN, Enver UCBILEK, Bunyamin SARITAS, et al. (2014). Chitotriosidase Activity in Different Stages of Hepatitis C. It may a Possible Tumor Marker for Hepatocellular Carcinoma. Journal of Cancer Treatment and Research, 2(1), 5-8. https://doi.org/10.11648/j.jctr.20140201.12

    Copy | Download

    ACS Style

    Engin ALTINTAS; Serkan Yaras; Burak CIMEN; Enver UCBILEK; Bunyamin SARITAS, et al. Chitotriosidase Activity in Different Stages of Hepatitis C. It may a Possible Tumor Marker for Hepatocellular Carcinoma. J. Cancer Treat. Res. 2014, 2(1), 5-8. doi: 10.11648/j.jctr.20140201.12

    Copy | Download

    AMA Style

    Engin ALTINTAS, Serkan Yaras, Burak CIMEN, Enver UCBILEK, Bunyamin SARITAS, et al. Chitotriosidase Activity in Different Stages of Hepatitis C. It may a Possible Tumor Marker for Hepatocellular Carcinoma. J Cancer Treat Res. 2014;2(1):5-8. doi: 10.11648/j.jctr.20140201.12

    Copy | Download

  • @article{10.11648/j.jctr.20140201.12,
      author = {Engin ALTINTAS and Serkan Yaras and Burak CIMEN and Enver UCBILEK and Bunyamin SARITAS and Fehmi ATES and Orhan SEZGIN and Gulhan OREKECI},
      title = {Chitotriosidase Activity in Different Stages of Hepatitis C. It may a Possible Tumor Marker for Hepatocellular Carcinoma},
      journal = {Journal of Cancer Treatment and Research},
      volume = {2},
      number = {1},
      pages = {5-8},
      doi = {10.11648/j.jctr.20140201.12},
      url = {https://doi.org/10.11648/j.jctr.20140201.12},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20140201.12},
      abstract = {Chitotriosidase is synthesized and secreted especially in activated macrophages. The aim of this study was to evaluate chitotriosidase activity in patients with various stages of hepatitis C. The study included a total of 90 patients. The patients were divided into four groups. Group 1 included 54 patients with chronic active hepatitis, Group 2 included 20 patients with recovered HCV, Group 3 included 6 patients with HCV induced hepatocellular carcinoma, and Group 4 included 10 patients with HCV cirrhosis. Chitotriosidase activity was measured with spectrophotometry (SigmaAldrich ®). The mean chitotriosidase activity of the four groups was 0,927u/L (0.804u/L in Group 1, 0.521u/L in Group 2, 3.211u/L in Group 3 and 1.030u/L in Group 4). Chitotriosidase activity was significantly higher in Group 3. ROC analysis, used to evaluate chitotriosidase activity for the diagnosis of hepatocellular carcinoma, showed that chitotriosidase activity of 0,935 was below the curve (CI: 95%; 0,862 - 0,976), which was statistically significant (p= 0,0001). The cut-off value was >1,098 with a sensitivity of 100% and a specifity of 81%. Chitotriosidase activity can be a marker with a high sensitivity and specifity for the diagnosis of hepatocellular carcinoma.},
     year = {2014}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Chitotriosidase Activity in Different Stages of Hepatitis C. It may a Possible Tumor Marker for Hepatocellular Carcinoma
    AU  - Engin ALTINTAS
    AU  - Serkan Yaras
    AU  - Burak CIMEN
    AU  - Enver UCBILEK
    AU  - Bunyamin SARITAS
    AU  - Fehmi ATES
    AU  - Orhan SEZGIN
    AU  - Gulhan OREKECI
    Y1  - 2014/03/10
    PY  - 2014
    N1  - https://doi.org/10.11648/j.jctr.20140201.12
    DO  - 10.11648/j.jctr.20140201.12
    T2  - Journal of Cancer Treatment and Research
    JF  - Journal of Cancer Treatment and Research
    JO  - Journal of Cancer Treatment and Research
    SP  - 5
    EP  - 8
    PB  - Science Publishing Group
    SN  - 2376-7790
    UR  - https://doi.org/10.11648/j.jctr.20140201.12
    AB  - Chitotriosidase is synthesized and secreted especially in activated macrophages. The aim of this study was to evaluate chitotriosidase activity in patients with various stages of hepatitis C. The study included a total of 90 patients. The patients were divided into four groups. Group 1 included 54 patients with chronic active hepatitis, Group 2 included 20 patients with recovered HCV, Group 3 included 6 patients with HCV induced hepatocellular carcinoma, and Group 4 included 10 patients with HCV cirrhosis. Chitotriosidase activity was measured with spectrophotometry (SigmaAldrich ®). The mean chitotriosidase activity of the four groups was 0,927u/L (0.804u/L in Group 1, 0.521u/L in Group 2, 3.211u/L in Group 3 and 1.030u/L in Group 4). Chitotriosidase activity was significantly higher in Group 3. ROC analysis, used to evaluate chitotriosidase activity for the diagnosis of hepatocellular carcinoma, showed that chitotriosidase activity of 0,935 was below the curve (CI: 95%; 0,862 - 0,976), which was statistically significant (p= 0,0001). The cut-off value was >1,098 with a sensitivity of 100% and a specifity of 81%. Chitotriosidase activity can be a marker with a high sensitivity and specifity for the diagnosis of hepatocellular carcinoma.
    VL  - 2
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Mersin University Faculty of Medicine, Gastroenterology Dept., Mersin, Türkiye

  • Mersin University Faculty of Medicine, Gastroenterology Dept., Mersin, Türkiye

  • Mersin University Faculty of Medicine, Biochemistry Dept., Mersin, Türkiye

  • Mersin University Faculty of Medicine, Gastroenterology Dept., Mersin, Türkiye

  • Mersin University Faculty of Medicine, Gastroenterology Dept., Mersin, Türkiye

  • Mersin University Faculty of Medicine, Gastroenterology Dept., Mersin, Türkiye

  • Mersin University Faculty of Medicine, Gastroenterology Dept., Mersin, Türkiye

  • Mersin University Faculty of Medicine, Biochemistry Dept., Mersin, Türkiye

  • Sections